Theravectys SA - Product Pipeline Review - 2016

Published: Oct, 2016 | Pages: 44 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Theravectys SA - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Theravectys SA - Product Pipeline Review - 2016', provides an overview of the Theravectys SA's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Theravectys SA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Theravectys SA
- The report provides overview of Theravectys SA including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Theravectys SA's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Theravectys SA's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Theravectys SA's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Theravectys SA
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Theravectys SA's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Theravectys SA Snapshot 6
Theravectys SA Overview 6
Key Facts 6
Theravectys SA - Research and Development Overview 7
Key Therapeutic Areas 7
Theravectys SA - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Theravectys SA - Pipeline Products Glance 12
Theravectys SA - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Theravectys SA - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Theravectys SA - Drug Profiles 14
Cellular Immunotherapy to Inhibit PD1 for Oncology - Drug Profile 14
Product Description 14
Mechanism Of Action 14
R&D Progress 14
Cellular Immunotherapy to Target CD33 and CD123 for AML - Drug Profile 15
Product Description 15
Mechanism Of Action 15
R&D Progress 15
Cellular Immunotherapy to Target CTLA4 for Oncology - Drug Profile 16
Product Description 16
Mechanism Of Action 16
R&D Progress 16
Cellular Immunotherapy to Target PDL1 for Oncology - Drug Profile 17
Product Description 17
Mechanism Of Action 17
R&D Progress 17
Epstein-Barr virus vaccine - Drug Profile 18
Product Description 18
Mechanism Of Action 18
R&D Progress 18
hepatitis B vaccine - Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
THV-01 - Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
THV-02 - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
THV-03 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
THV-04 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
Vaccine for Breast Cancer - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Vaccine for Glioblastoma Multiforme - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
Vaccine for Hepatocellular Carcinoma - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Vaccine for HPV Associated Cancers - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Vaccine for Melanoma - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Vaccine for Multiple Myeloma - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Vaccine for Ovarian Cancer - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Vaccine for Prostate Cancer - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Vaccine to Target CD274 and CD279 for Bladder Cancer - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Vaccine to Target CD274 and CD279 for Colorectal Cancer - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Vaccine to Target CD274 and CD279 for Renal Cell Carcinoma - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Theravectys SA - Pipeline Analysis 36
Theravectys SA - Pipeline Products by Target 36
Theravectys SA - Pipeline Products by Route of Administration 38
Theravectys SA - Pipeline Products by Molecule Type 39
Theravectys SA - Pipeline Products by Mechanism of Action 40
Theravectys SA - Dormant Projects 41
Theravectys SA - Locations And Subsidiaries 42
Head Office 42

Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44

List of Tables

Theravectys SA, Key Facts 6
Theravectys SA - Pipeline by Indication, 2016 9
Theravectys SA - Pipeline by Stage of Development, 2016 10
Theravectys SA - Monotherapy Products in Pipeline, 2016 11
Theravectys SA - Phase II, 2016 12
Theravectys SA - Preclinical, 2016 13
Theravectys SA - Pipeline by Target, 2016 37
Theravectys SA - Pipeline by Route of Administration, 2016 38
Theravectys SA - Pipeline by Molecule Type, 2016 39
Theravectys SA - Pipeline Products by Mechanism of Action, 2016 40
Theravectys SA - Dormant Developmental Projects,2016 41